XNCR:  Xencor announces that Alexion Pharmaceuticals, informed Xencor, that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any future payments for sales in the United States  (12.74 +0.72)